Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 91Rituximab 80Specimen Handling 75Magnetic Resonance Spectroscopy 64Biopsy 59Doxorubicin 48Prednisone 47Vincristine 46venetoclax 38obinutuzumab 35fludarabine 34ibrutinib 29Lenalidomide 29Dexamethasone 27Cytarabine 27Methotrexate 25Etoposide 24prednylidene 23CT-P10 23zanubrutinib 22deltacortene 22blinatumomab 22acalabrutinib 22fludarabine phosphate 21Nivolumab 21merphos 18pembrolizumab 16Bendamustine Hydrochloride 16Mercaptopurine 15Calcium Dobesilate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
olverembatinib × Lymphoid × 30 days × Clear all
NCT07454226 2026-05-13

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Recruiting
92 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡